As digital health adoption accelerates, the market is entering a new phase - one shaped less by novelty and more by integration. Analysts project the sector will expand from roughly $8.7 billion in 2025 to nearly ~$18 billion by 2035, driven by the convergence of remote monitoring, personalized care, and employer demand for cost-efficient chronic-condition management.
Within that growth arc, multi-condition platforms - those addressing several chronic diseases through one ecosystem - may hold the most durable long-term potential. Yet among the public players in this category, valuations vary widely. DarioHealth (NASDAQ: DRIO), a smaller but highly specialized platform, trades well below peers such as Hinge Health (NYSE: HNGE), Omada Health (NASDAQ: OMDA), and Wellgistics Health (NASDAQ: WGRX) despite demonstrating a fully built, clinically validated model.
A Sector in Transition
Digital health’s first wave was defined by specialization - companies like Hinge Health focusing narrowly on musculoskeletal care or Omada Health expanding gradually from diabetes prevention into cardiometabolic management. The next phase is being defined by integration, as employers and payers increasingly favor single vendors capable of managing multiple chronic conditions across physical and behavioral dimensions.
DarioHealth sits at the center of that shift. Its platform unites diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health under one connected interface. This design aligns with a clear trend in enterprise healthcare: a preference for fewer partners delivering broader impact, especially as chronic conditions account for the majority of U.S. healthcare spending.
Under the Radar: Why Dario Might be Trading at a Major Discount
At a fraction of many peers’ valuations, the gap around DarioHealth likely seems to reflect a company in transition - one that began as a consumer diabetes-device maker and has since evolved into a recurring-revenue SaaS platform serving employers and health plans. The effects of that transformation are already visible in the numbers.
In the second quarter of 2025, DarioHealth reported $5.4 million in revenue, compared with $6.3 million in the same period a year earlier. But that that decline repotedly stemmed largely from a single health-plan client’s internal restructuring rather than weakness in demand, and in many ways has temporarily obscured the progress underneath. Beneath that surface-level dip, the company seems to have quietly delivered four consecutive quarters of gross margins above 80% in its B2B2C business, while operating expenses have fallen 36% year-over-year as efficiency programs take hold.
Positioned for the GLP-1 Era
A major catalyst now reshaping the entire chronic-care landscape is the GLP-1 drug revolution - medications like Ozempic, Wegovy, Mounjaro, and Zepbound that have redefined treatment for obesity and diabetes. Tens of millions of U.S. adults could be eligible for GLP-1 therapy, with one study estimating over 100 million, and actual users already numbering in the millions.
That is precisely where Dario’s design stands out. Its integrated behavioral, nutritional, and musculoskeletal modules are built to manage the full GLP-1 member journey - from adherence and lifestyle modification to side-effect mitigation. Larger peers such as Omada have begun to build GLP-1 companion programs, but none yet cover the complete continuum of care. Hinge Health, with its narrower musculoskeletal focus, cannot.
As self-insured employers increasingly require comprehensive digital support as a prerequisite for reimbursing GLP-1 therapies, multi-indication platforms like Dario’s could become critical infrastructure rather than optional add-ons.
The Road Ahead
Execution remains key. Dario signed 21 new clients year-to-date and aims to double that by the end of 2025. Achieving those goals will determine whether its transition translates into scale. Management targets cash-flow breakeven by late 2026 or early 2027, aided by continued automation and AI-driven cost optimization.
Meanwhile, peers illustrate contrasting paths: Hinge Health commands a multibillion-dollar valuation based on rapid top-line growth but operates within a narrower clinical lane. Omada Health continues expanding revenue yet remains unprofitable. Wellgistics Health, despite broad distribution reach, has struggled with leadership changes and operational clarity.
Against that backdrop, DarioHealth’s disciplined repositioning and improving fundamentals suggest the market may simply be behind the curve in recognizing its strategic reset.
Conclusion: The Quiet Compounding Underdog
As the digital health market doubles over the next decade, consolidation around integrated, outcome-driven platforms appears inevitable. DarioHealth’s five-condition architecture, strong gross margins, and visible path to profitability seem to position it squarely within that coming convergence.
While investors have rewarded category specialists with premium valuations, DarioHealth represents the other side of the trade: a multi-condition platform that seems to be quietly compounding value beneath the market’s radar. Should sentiment shift toward integrated models and recurring-revenue efficiency, the company’s current discount could prove less a verdict - and more an opportunity.
Recent News Highlights from Dario:
Important Legal Disclaimers, Terms & Disclosures:
By using CapNotes, any related brands thereof, and any affiliated or partner websites operated under the Wall Street Wire Network (collectively referred to as “Services”), you acknowledge that any and all Services provided are for informational and entertainment purposes only and do not constitute a recommendation for any particular stock, company, investment, commodity, security, transaction, or any other method of trading featured anywhere on CapNotes or affiliated platforms. CapNotes does not guarantee the accuracy, completeness, or timeliness of the information or Services provided. Views and opinions presented through the Services, whether expressed by contributors, columnists, external partners, or employees, are not specifically endorsed by CapNotes or the Wall Street Wire Network, and neither entity accepts responsibility or liability for any actions, financial or otherwise, taken directly or indirectly as a result of engaging with any of the Services offered.
CapNotes, its employees, operator, partners, affiliates, and any other representatives will not, either directly or indirectly, be held liable, accountable, or responsible in any capacity to you or to any third party for any errors, inaccuracies, or omissions from the Services, including but not limited to market quotes, rumors, unverified chatter, financial data, and news reports; for any interruptions, delays, or transmission errors affecting the availability or accuracy of the Services; or for any damages or losses arising from or related to the use of, reliance on, or inability to access the Services. Some content published by CapNotes may reference market rumors, speculative chatter, or unconfirmed reports. Readers should be aware that while such unofficial information may be associated with market volatility, price movements based on speculative or incomplete data are subject to change rapidly upon further clarification or the release of official news or filings.
CapNotes reserves the right at any time to modify any part of its Terms of Service or any portion of the Services, including but not limited to the removal or addition of content, features, contributors, or affiliated content providers, or the introduction of any associated fees or usage conditions. Such changes will take effect immediately upon their publication across the Services and will apply to all users from the time of posting. Please note that trading in foreign currencies, stocks, options, and other securities involves substantial risk and may result in significant financial losses. Neither CapNotes nor its staff recommends that you buy, sell, or hold any security, and no part of the Services constitutes personalized investment advice. All information provided through the Services is general commentary intended for informational and entertainment use only. CapNotes disclaims any liability for loss or damage, including without limitation any loss of capital, profit, or opportunity, that may arise directly or indirectly from use of or reliance on the information contained within the Services. We encourage all users to conduct their own due diligence and consult with a certified financial advisor or licensed professional before making any financial decisions.
Content produced by or for CapNotes may not be reproduced, republished in full, or redistributed in any form without prior written permission from CapNotes or the Wall Street Wire Network, as applicable.
This content is a form of paid promotional content and advertising. Wall Street Wire receives cash compensation from DarioHealth Corp for promotional media services provided on an ongoing subscription basis. This content is for informational purposes only and does not constitute financial advice. Wall Street Wire is not a broker-dealer or investment adviser. Full compensation details and information regarding the operator of Wall Street Wire are available wallstwire.ai/disclosures. We are not responsible for any market size figures that may be cited in this article nor do we endorse them, they are quoted based on publicly available news reports and additional price targets or figures may exist that may not have been quoted. This article should not be considered an official communication by the issuer.